Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abbott Laboratories ( (ABT) ) has shared an announcement.
On April 24, 2026, Abbott Laboratories expanded its board to 13 members and appointed Kevin Conroy as a director, following a by-law amendment approved the same day. At its Annual Meeting on April 24, 2026, shareholders also re-elected the full slate of directors and ratified Ernst & Young LLP as the company’s auditor, signaling broad investor support for existing governance structures.
Shareholders overwhelmingly approved Abbott’s 2026 Incentive Stock Program, replacing the 2017 plan with a new 10-year equity incentive framework authorizing up to 140 million shares plus recycling of certain shares from the prior plan. Investors also backed executive compensation and endorsed a 2026 Employee Stock Purchase Plan for non-U.S. employees, reinforcing Abbott’s ability to use equity-based pay to attract and retain talent globally while aligning management and employee incentives with shareholder interests.
The most recent analyst rating on (ABT) stock is a Buy with a $108.00 price target. To see the full list of analyst forecasts on Abbott Laboratories stock, see the ABT Stock Forecast page.
Spark’s Take on ABT Stock
According to Spark, TipRanks’ AI Analyst, ABT is a Neutral.
The score is supported by strong cash flow and a constructive earnings outlook (mid-to-high single-digit comparable sales growth, strong device performance) but held back by weak technicals (below key moving averages with negative momentum), a relatively high P/E with a modest dividend yield, and uncertainty from earnings volatility and incomplete 2025 balance sheet data.
To see Spark’s full report on ABT stock, click here.
More about Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a broad range of medical devices, diagnostics, branded generic pharmaceuticals, and nutrition products. The company focuses on serving hospitals, laboratories, physicians, and consumers worldwide, with a strong emphasis on diagnostics, cardiovascular and neuromodulation devices, and chronic disease management solutions.
Average Trading Volume: 11,699,676
Technical Sentiment Signal: Sell
Current Market Cap: $158.7B
See more data about ABT stock on TipRanks’ Stock Analysis page.